Future Directions in Advanced Endometrial Carcinoma
Closing the discussion on advanced endometrial carcinoma, Dr David O’Malley shares his perspective on the future treatment landscape.
Additional Highlights from SGO 2023
David O’Malley, MD, an expert on advanced endometrial carcinoma, shares additional highlights presented at SGO 2023.
Patient Tolerability with Lenvatinib plus Pembrolizumab
David O’Malley, MD, details patient tolerance and associated adverse events with lenvatinib plus pembrolizumab for advanced endometrial carcinoma.
KEYNOTE-775: Updates from SGO 2023
An expert gynecologic oncologist reviews recent updates presented at SGO 2023 from the KEYNOTE-775 trial for advanced endometrial carcinoma.
Standard Treatments for Patients with Advanced Endometrial Carcinoma
A brief review of the current treatment armamentarium for advanced endometrial carcinoma.
Molecular Profiling and Risk Stratification in Advanced Endometrial Carcinoma
David O’Malley, MD, an expert gynecologic oncologist, details molecular profiling and risk stratification for patients with advanced endometrial carcinoma.
Overview of Endometrial Carcinoma
David O’Malley, MD, provides a comprehensive overview of endometrial carcinoma and treatment options for patients in this setting.
David O’Malley, MD, Discusses PFS Benefit of Maintenance Rucaparib Regardless of Surgery Outcome in Newly Diagnosed Ovarian Cancer
Data from the phase 3 ATHENA-MONO study indicated that maintenance rucaparib yielded progression-free survival benefit vs placebo across all subgroups in a population of patients newly diagnosed ovarian cancer, according to David O’Malley, MD.
David M. O’Malley, MD, Talks Next Steps for Treatment in Endometrial Cancer
David M. O’Malley, MD, spoke about where the future of treatment is heading for patients with endometrial cancer.
David M. O’Malley, MD, Reviews the Benefit of Pembrolizumab for Endometrial Cancer
David M. O’Malley, MD, spoke about unmet needs of patients with advanced microsatellite instability–¬high or mismatch repair deficient endometrial carcinoma and the clinical benefit pembrolizumab provides.
David M. O’Malley, MD, Discusses Recent Approval of Pembrolizumab in Endometrial Cancer
David M. O’Malley, MD, spoke about the approval of pembrolizumab for patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient.
David O’Malley, MD, Discusses Findings From the OReO Trial in Ovarian Cancer at 2021 ESMO
CancerNetwork® sat down with David O’Malley, MD, at the 2021 European Society for Medical Oncology to talk about the OReO trial and how these findings impact what’s already known about PARP inhibitors for the treatment of ovarian cancer.
2 Clarke Drive Cranbury, NJ 08512